Sentinel Trust Co. LBA Invests $3.85 Million in Bristol-Myers Squibb Co (NYSE:BMY)

Sentinel Trust Co. LBA acquired a new position in Bristol-Myers Squibb Co (NYSE:BMY) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 69,580 shares of the biopharmaceutical company’s stock, valued at approximately $3,850,000.

Other large investors have also added to or reduced their stakes in the company. Riverhead Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 22.2% during the first quarter. Riverhead Capital Management LLC now owns 28,751 shares of the biopharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 5,217 shares during the period. US Bancorp DE lifted its stake in Bristol-Myers Squibb by 1.6% in the first quarter. US Bancorp DE now owns 2,261,015 shares of the biopharmaceutical company’s stock valued at $143,010,000 after buying an additional 34,576 shares during the period. Tyers Asset Management LLC lifted its stake in Bristol-Myers Squibb by 19.2% in the first quarter. Tyers Asset Management LLC now owns 29,084 shares of the biopharmaceutical company’s stock valued at $1,839,000 after buying an additional 4,686 shares during the period. Connecticut Wealth Management LLC lifted its stake in Bristol-Myers Squibb by 32.8% in the first quarter. Connecticut Wealth Management LLC now owns 4,422 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 1,093 shares during the period. Finally, Willingdon Wealth Management lifted its stake in Bristol-Myers Squibb by 21.6% in the first quarter. Willingdon Wealth Management now owns 85,550 shares of the biopharmaceutical company’s stock valued at $5,411,000 after buying an additional 15,182 shares during the period. Hedge funds and other institutional investors own 72.28% of the company’s stock.

NYSE:BMY opened at $62.90 on Tuesday. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46. The stock has a market cap of $101.47 billion, a P/E ratio of 20.90, a PEG ratio of 1.70 and a beta of 0.98. Bristol-Myers Squibb Co has a 52-week low of $49.96 and a 52-week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The business had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. Bristol-Myers Squibb’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company earned $0.74 earnings per share. On average, research analysts predict that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Friday, October 5th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.54%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.

BMY has been the topic of several analyst reports. BMO Capital Markets reissued a “hold” rating and issued a $47.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, June 21st. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Sunday, July 15th. Credit Suisse Group increased their price target on Bristol-Myers Squibb from $58.00 to $61.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. Finally, SunTrust Banks restated a “buy” rating and issued a $67.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $62.95.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: What Factors Can Affect Return on Equity?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply